Natalie E Cusano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8637487/publications.pdf

Version: 2024-02-01

304743 395702 2,260 35 22 33 h-index citations g-index papers 36 36 36 1675 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hyperparathyroidism. Lancet, The, 2018, 391, 168-178.	13.7	371
2	Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. Journal of Bone and Mineral Research, 2013, 28, 1029-1040.	2.8	174
3	The Effect of PTH(1–84) on Quality of Life in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2356-2361.	3.6	169
4	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	3.6	151
5	Therapy of Hypoparathyroidism with PTH(1–84): A Prospective Four-Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 137-144.	3.6	148
6	Normocalcemic Primary Hyperparathyroidism. Journal of Clinical Densitometry, 2013, 16, 33-39.	1.2	145
7	Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2734-2741.	3.6	116
8	Bone disease in primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 553-561.	1.3	104
9	PTH(1–84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3694-3699.	3.6	104
10	Therapy of Hypoparathyroidism With PTH($1\hat{a}\in 84$): A Prospective Six Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2742-2750.	3.6	101
11	Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 593-607.	4.7	81
12	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 308-316.	2.8	67
13	Management of normocalcemic primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 837-845.	4.7	55
14	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. Endocrine, 2017, 55, 591-598.	2.3	47
15	Primary Hyperparathyroidism: A Tale of Two Cities Revisited — New York and Shanghai. Bone Research, 2013, 1, 162-169.	11.4	45
16	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 196-205.	3.6	45
17	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2748-2756.	3.6	44
18	Mini-review: new therapeutic options in hypoparathyroidism. Endocrine, 2012, 41, 410-414.	2.3	32

#	Article	IF	CITATIONS
19	Signs and Symptoms of Hypoparathyroidism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 759-770.	3.2	32
20	Parathyroid hormone therapy for hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 47-55.	4.7	29
21	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1512-1521.	3.6	27
22	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. Journal of Bone and Mineral Research, 2018, 33, 1931-1939.	2.8	24
23	Combination Anabolic and Antiresorptive Therapy for Osteoporosis. Endocrinology and Metabolism Clinics of North America, 2012, 41, 643-654.	3.2	22
24	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Review of Endocrinology and Metabolism, 2015, 10, 5-13.	2.4	22
25	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2018, 33, 2132-2139.	2.8	19
26	Therapy of Osteoporosis in Men with Teriparatide. Journal of Osteoporosis, 2011, 2011, 1-7.	0.5	18
27	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 1082-1088.	2.8	18
28	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1–84) Therapy in Hypoparathyroidism. Journal of Bone and Mineral Research, 2020, 35, 1274-1281.	2.8	14
29	Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101247.	4.7	13
30	Parathyroid Hormone in the Evaluation of Hypercalcemia. JAMA - Journal of the American Medical Association, 2014, 312, 2680.	7.4	11
31	Parathyroid Hormone 1–84 Alters Circulating Vascular Endothelial Growth Factor Levels in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2025-E2028.	3.6	5
32	Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients. Medical Clinics of North America, 2021, 105, 1135-1150.	2.5	3
33	Primary Hyperparathyroidism after Laser Therapy to the Larynx. Endocrine Practice, 2013, 19, 888-890.	2.1	2
34	Smoking Is Associated with Sex-Specific Effects on Bone Microstructure in Older Men and Women. Journal of Clinical Densitometry, 2020, 24, 341-350.	1,2	1
35	Comparative effectiveness of combination osteoanabolic and antiresorptive therapy for osteoporosis: an update. Journal of Comparative Effectiveness Research, 2013, 2, 511-513.	1.4	0